ClinicalTrials.gg
RecruitingNCT04356287CARE-SScUpdated Feb 3, 2026

Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis

A Phase 1/2 interventional study of UCMSC and Placebo in Sclerosis, Systemic and Mesenchymal Stem Cells, sponsored by Marie Hudson, MD. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Marie Hudson, MD · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Scleroderma, Systemic with a site in Canada — 12 open to participants now, 13 under way, 4 of them phase 3. Scleroderma, Systemic · Canada.

Planned enrollment
33rd of 39
18 · median 115
Started
2023
with 2 others
Phase 1/2
Only one
of the 44
Primary completion
2026-12
later than 1 of 12 live
Registered
27th of 44
by date

Among the 44 studies in Scleroderma, Systemic with a site in Canada, this one is the 33rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, reaches primary completion later than 1 of the 12 other live ones, and was the 27th registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

12 of the 44 studies in Scleroderma, Systemic with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Scleroderma, Systemic with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) for the treatment of Systemic Sclerosis (SSc).

Read the detailed description

A single-center, three-arm, randomized, double-blind, placebo-controlled trial is proposed. A total of 18 SSc patients will be enrolled in 3 successive blocks of 6 patients each. After being informed about the study and potential risks, all patients giving written informed consent will be randomized to one of two treatment arms or a placebo arm (total of 6 patients per arm). Within each block, the 6 patients will be randomized in a 2:2:2 ratio in one of the following arms: placebo, 1 infusion of UCMSC (M0), or 2 infusions of UCMSC (M0, M3). Second infusions of UCMSC will be performed only in the absence of Treatment Related Severe Adverse Events (TRSAE). Randomization into blocks 2 and 3 will be staggered, to allow the detection of TRSAE prior to inclusion of patients in a subsequent block, i.e. the second block will be randomized only in the absence of TRSAE one month after the first infusion of all 6 patients in block one, and similarly for the third block.

03

Conditions studied

  • Sclerosis, Systemic
  • Mesenchymal Stem Cells

Browse trials for

Keywords

  • Systemic Sclerosis
  • Umbilical cord-derived mesenchymal stromal cells
  • Scleroderma, Systemic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. SSc according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2103 classification criteria for systemic sclerosis
  2. Severe disease defined as:

    i) disease duration of 2 years or less with an mRss of > 20 and (ESR > 25 mm and/or \< 11 g/dL, not explained by other causes than SSc), or ii) mRss >15 without any restriction as to disease duration plus at least one major organ involvement as defined by: a) respiratory involvement consisting of lung diffusion capacity for carbon monoxide (DLCO) and/or forced vital capacity (FVC) \< 80% predicted and evidence of interstitial lung disease (chest X-ray and/or high resolution computed tomography (HRCT) scan); b) renal involvement consisting of past renal crisis and/or stage 2 or 3 chronic kidney disease ( between 30-89 mL/min) not explained by other causes than SSc; c) cardiac involvement consisting of reversible congestive heart failure, atrial or ventricular rhythm disturbances such as recurrent episodes of atrial fibrillation or flutter, recurrent atrial paroxysmal tachycardia, conduction abnormalities (2nd or 3rd degree atrioventricular block), and/or mild to moderate pericardial effusion. All causes of organ involvement should be attributed to SSc.

  3. Inadequate response (determined by patient and physician judgement) or adverse events necessitating discontinuation of standard therapy (usually consisting of methotrexate 25 mg subcutaneous (or as tolerated) per week and/or mycophenolate mofetil 2-3 gm/d (or as tolerated) for at least 3 months
  4. Ineligibility or unwillingness to undergo hematopoietic stem cell transplant

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years
  2. Pregnancy or unwillingness to use adequate
  3. Life-threatening end-organ damage defined as:

    • FVC \< 45% and/or DLCO (corrected for ) \< 30% predicted;
    • \< 40% by cardiac echocardiography;
    • Pulmonary hypertension with baseline resting systolic pulmonary arterial pressures > 50 mmHg by cardiac echocardiography, or mean pulmonary artery pressure > 25 mmHg (and pulmonary wedge pressure \< 15 mmHg) on right heart catheterization;
    • stage 4 or more chronic kidney disease ( \< 30 ml/min)
  4. Liver failure defined as an abnormal transaminase level ( (ASAT), alanine aminotransaminase (ALAT) > 3 normal) unless related to activity of the disease
  5. Concurrent neoplasms or myelodysplasia
  6. Uncontrolled hypertension
  7. Uncontrolled acute or chronic infection (, HTLV-1/2 (Human T-lymphotropic virus), surface Ag positive, positive) or high risk thereof
  8. Significant malnutrition with \< 18 kg/m2
  9. Severe concomitant psychiatric disorder
  10. Bone marrow insufficiency defined as neutropenia \< 0.5 x 109 cell/L, thrombocytopenia \< 30 x 109 cell/L, anemia \< 8g/dL, CD4+ T lymphopenia \< 200 x 106 cell/L due to other diseases than SSc (CD4 - cluster of differentiation 4)
  11. History of poor compliance
  12. Concurrent enrolment in any other protocol using an drug
  13. Inability to provide
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    One infusion of UCMSC

    Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.

    Biological: UCMSC

  • Experimental
    Two infusions of UCMSC

    Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.

    Biological: UCMSC

  • Placebo comparator
    Placebo infusions

    Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.

    Other: Placebo

Interventions

  • BiologicalUCMSC

    Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.

    Also known as: umbilical cord derived mesenchymal stromal cells

  • OtherPlacebo

    Each infusion will consist of 50 mL of PlasmaLyte A.

06

What researchers measure

Primary outcomes

  1. Measure of safety one month after first infusion

    Treatment related severe adverse event using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification \[https://ctep.cancer.gov/protocolDevelopment/electronic\_applications/ctc.htm\]

    Time frame: Month 1

Secondary outcomes

  1. Change in modified Rodnan skin score (mRss) between Month 0 and Month 12

    A measure of skin thickness; difference between Month 12 and Month 0 on the mRss \[Khanna et al., 2017\]

    Time frame: Month 0 and Month 12

Other outcomes

  1. Safety at the time of infusion, 24 hours, 10 days +/- 24 hours, Month 6, Month 9 and Month 12 (adverse events)

    Measure of safety of UCMSC in severe SSc using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification \[https://ctep.cancer.gov/protocolDevelopment/electronic\_applications/ctc.htm\]

    Time frame: 24 hours, 10 days +/- 24 hours, Month 6, Month 9 and Month 12

  2. Mortality occurring after randomization and up to study completion

    Causes of death and their relation to SSc versus the study intervention will be evaluated by the Data and Safety Monitoring Committee (DSMC).

    Time frame: 1 year

  3. Modified Rodnan skin score

    A measure of skin thickness \[Khanna et al., 2017\]

    Time frame: Month 0, Month 3, Month 6 and Month 9

  4. World Health Organization (WHO) performance status

    WHO performance status \[Oken et al., 1982\] describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.).

    Time frame: Month 0, Month 3, Month 6, Month 9 and Month 12

  5. Scleroderma-Health Assessment Questionnaire

    Disease status as measured by the Scleroderma-Health Assessment Questionnaire \[Steen \& Medsger, 1997\]

    Time frame: Month 0, Month 3, Month 6, Month 9 and Month 12

  6. 36-Item Short Form Survey version 2 for health-related quality of life (SF-36v2)

    Health-related quality of life as measured by the SF-36v2 \[Ware et al., 2007\]

    Time frame: Month 0, Month 3, Month 6, Month 9 and Month 12

  7. EuroQoL health status measure (EQ-5D-5L)

    Health related quality of life in cost effectiveness analysis as measured by the EQ-5D-5L \[Herdman et al., 2011\] using five levels of severity in five dimensions.

    Time frame: Month 0, Month 3, Month 6, Month 9 and Month 12

  8. Response to treatment

    Defined as decrease in mRss \> 25%, increase in FVC \> 10% predicted (forced vital capacity) and/or increase in DLCO \>15% predicted (diffusing capacity of the lungs for carbon monoxide), without need for further immunosuppression except low dose steroids

    Time frame: Month 0, Month 12

  9. Progression-free survival

    Progression defined as any one of the following: decrease in FVC \> 10% predicted; decrease in DLCO \> 15% predicted; decrease in left ventricular ejection fraction on cardiac echocardiography \> 15%; decrease in weight \> 15%; decrease in creatinine clearance \> 30%; increase in mRss \> 25%; and/or increase in Scleroderma-Health Assessment Questionnaire \> 0.5

    Time frame: Month 0, Month 12

  10. Global Rank Composite Score

    A composite score consisting of a hierarchy of ordered outcomes: death, event-free survival (survival without respiratory, renal, or cardiac failure), FVC, score on the Disability Index of the Health Assessment Questionnaire (HAQ-DI; range, 0 to 3, with higher scores indicating more disability), and the modified Rodnan skin score. \[Sullivan et al., 2018\]

    Time frame: Month 0, Month 12

  11. ACR Provisional Composite Response Index

    ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (CRISS) \[Khanna et al., 2016\], a composite measure of treatment response in SSc

    Time frame: Month 0, Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Reports. 2018 Mar 13;10(3):933-941. doi: 10.1016/j.stemcr.2018.01.029. Epub 2018 Mar 1. PubMed 29478901 ↗
  • Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X, Zhao C, Hua B, Wang H, Sun L. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018 Nov 14;9(1):312. doi: 10.1186/s13287-018-1053-4. PubMed 30428931 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2020
First posted
Apr 22, 2020
StartActual
Jan 5, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04356287
Lead sponsor
Marie Hudson, MD
Responsible party
Marie Hudson, MD (Rheumatologist, Jewish General Hospital; Physician-scientist, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis - Jewish General Hospital) — Sponsor-investigator
First posted
Apr 22, 2020
Start date
Jan 5, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 3, 2026

Study contacts

Marie Hudson, MD
Contact
marie.hudson@mcgill.ca
514-340-8222 ext. 23476
Marie Hudson, MD
principal investigator · Sir Mortimer B. Davis - Jewish General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion